Regulation Tracker
FDA PCAC July 2026: what's being reviewed
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviews seven peptides for the 503A approved bulks list. BPC-157 is the one to watch.
Meeting: July 23–24, 2026
The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviews seven peptides for the 503A approved
bulks list. The committee's recommendation is advisory — the FDA makes the final
determination — but PCAC recommendations carry substantial weight.The seven compounds under review
| Peptide | Commonly used for | What's at stake |
|---|---|---|
| BPC-157 | Tissue & gut repair | Staff briefing proposes NOT adding to the 503A bulks list — the headline risk |
| KPV | Anti-inflammatory | Inclusion on the bulks list |
| TB-500 | Recovery, tissue repair | Inclusion on the bulks list |
| MOTS-C | Metabolic / mitochondrial | Inclusion on the bulks list |
| DSIP (Emideltide) | Sleep | Inclusion on the bulks list |
| Semax | Cognitive | Inclusion on the bulks list |
| Epitalon | Longevity | Inclusion on the bulks list |
What the 503A bulks list actually controls
Compounding pharmacies may only use bulk drug substances that appear on — or remain eligible for — the FDA's approved list under Section 503A. A peptide on the list can be compounded against a prescription without ambiguity. A peptide left off it faces restrictions that flow directly through to whether a telehealth provider can get your prescription filled.
BPC-157 is the one to watch
An FDA staff briefing ahead of the meeting proposes BPC-157 not be added. That would not be an
outright ban — but it would restrict how compounding pharmacies can legally prepare it, which is the
practical mechanism by which prescribed access tightens. Given BPC-157's popularity, this is the single
most consequential item on the agenda.What to do before July 24
- Already on a protocol? Ask your provider directly about continuity plans if the bulks-list recommendation goes against your compound.
- Considering starting? Understand that the regulatory floor may shift. See where BPC-157 is currently prescribed.
- Weighing research-grade instead? Note that FDA enforcement is actively targeting "research use only" peptide sellers whose marketing implies human use. Read the comparison.
We'll publish the outcome
Veritide will cover the votes and what each decision means for prescribed access. Bookmark
The Ledger, and read our
plain-English briefing on what this means for you.FAQ
What is the FDA PCAC?
The Pharmacy Compounding Advisory Committee advises the FDA on which bulk drug substances may be used in 503A compounding. Its recommendations are advisory, but they carry substantial weight in the FDA's final determinations.
Which peptides are being reviewed in July 2026?
Seven: BPC-157, KPV, TB-500, MOTS-C, DSIP (Emideltide), Semax, and Epitalon. BPC-157 is the most consequential, as a staff briefing proposes it not be added to the approved bulks list.
What happens if BPC-157 isn't added to the bulks list?
Compounding pharmacies would face tighter restrictions on preparing it. That's not an outright ban, but it's the practical mechanism by which prescribed access narrows — telehealth providers would find it harder to get prescriptions filled.
Medical disclaimer: Veritide is an independent consumer-research publication, not a healthcare provider or pharmacy. This page is informational and is not medical advice. Compounded medications are not FDA-approved as finished products. Always consult a licensed clinician before starting any peptide or GLP-1 therapy.